INTANGIBLE ASSETS IN INDIAN PHARMACEUTICALS: DISCLOSURE PRACTICES AND IMPACT ON VALUE CREATION

This study analyzed intangible asset (IA) disclosure, trends, and value creation impact in ten Nifty Pharma companies (2015-21). Piramal Enterprises Ltd. led in both mandatory and voluntary disclosures. While most companies showed increasing IA values, their impact on value creation varied. Aurobindo Pharma and Glenmark showed significant IA impact on ROE, ROIC, Tobin's Q, and PB ratio, while Cadila, Divi's, and Dr. Reddy's saw impact on EVA. However, IA had no significant impact on firm value for Biocon, Cipla, Lupin, Piramal, and Sun Pharma in these specific metrics. Overall, IA significantly impacted profitability (ROA, ROE, ROIC, PAT) and firm value (Tobin's Q). Suggestions include improving disclosure for Cadila and Sun Pharma, boosting IA values for Divi's and Lupin, and continuing IA prioritization for Aurobindo and Glenmark to maximize stakeholder value.